Topline data were announced from a phase 3 trial demonstrating ONS-5010 (#BevacizumabVikg) was noninferior to #Ranibizumab at week 12 for the treatment of neovascular age-related macular degeneration (#WetAMD). 

Read more:#ONS5010 #Ophthalmology #MedTwitter